These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 21486038

  • 1. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
    Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB.
    J Med Chem; 2011 May 12; 54(9):3206-21. PubMed ID: 21486038
    [Abstract] [Full Text] [Related]

  • 2. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.
    Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C.
    Eur Neuropsychopharmacol; 2013 Feb 12; 23(2):133-45. PubMed ID: 22612991
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
    Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB.
    J Pharmacol Exp Ther; 2012 Mar 12; 340(3):666-75. PubMed ID: 22171087
    [Abstract] [Full Text] [Related]

  • 4. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.
    Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N.
    Int J Neuropsychopharmacol; 2013 Jun 12; 16(5):1115-27. PubMed ID: 23089374
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors.
    Orús L, Pérez-Silanes S, Oficialdegui AM, Martínez-Esparza J, Del Castillo JC, Mourelle M, Langer T, Guccione S, Donzella G, Krovat EM, Poptodorov K, Lasheras B, Ballaz S, Hervías I, Tordera R, Del Río J, Monge A.
    J Med Chem; 2002 Sep 12; 45(19):4128-39. PubMed ID: 12213056
    [Abstract] [Full Text] [Related]

  • 6. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
    Stenkrona P, Halldin C, Lundberg J.
    Eur Neuropsychopharmacol; 2013 Oct 12; 23(10):1190-8. PubMed ID: 23428337
    [Abstract] [Full Text] [Related]

  • 7. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission.
    Riga MS, Sánchez C, Celada P, Artigas F.
    Neuropharmacology; 2016 Sep 12; 108():73-81. PubMed ID: 27106166
    [Abstract] [Full Text] [Related]

  • 8. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission.
    Pehrson AL, Jeyarajah T, Sanchez C.
    CNS Spectr; 2016 Apr 12; 21(2):162-83. PubMed ID: 26250622
    [Abstract] [Full Text] [Related]

  • 9. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A, Matsui T, Hayashi H, Tamaoki S, Yamauchi Y, Minato K, Sato M.
    J Med Chem; 2010 Nov 11; 53(21):7549-63. PubMed ID: 20931963
    [Abstract] [Full Text] [Related]

  • 10. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
    Martínez-Esparza J, Oficialdegui AM, Pérez-Silanes S, Heras B, Orús L, Palop JA, Lasheras B, Roca J, Mourelle M, Bosch A, Del Castillo JC, Tordera R, Del Río J, Monge A.
    J Med Chem; 2001 Feb 01; 44(3):418-28. PubMed ID: 11462981
    [Abstract] [Full Text] [Related]

  • 11. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Orjales A, Mosquera R, Toledo A, Pumar MC, García N, Cortizo L, Labeaga L, Innerárity A.
    J Med Chem; 2003 Dec 04; 46(25):5512-32. PubMed ID: 14640559
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
    Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C.
    J Med Chem; 2004 Sep 09; 47(19):4684-92. PubMed ID: 15341484
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7.
    Gu ZS, Zhou AN, Xiao Y, Zhang QW, Li JQ.
    Eur J Med Chem; 2018 Jan 20; 144():701-715. PubMed ID: 29291438
    [Abstract] [Full Text] [Related]

  • 14. Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity.
    Yoshinaga H, Nishida T, Sasaki I, Kato T, Oki H, Yabuuchi K, Toyoda T.
    Bioorg Med Chem; 2018 May 01; 26(8):1614-1627. PubMed ID: 29456112
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
    Asproni B, Pau A, Bitti M, Melosu M, Cerri R, Dazzi L, Seu E, Maciocco E, Sanna E, Busonero F, Talani G, Pusceddu L, Altomare C, Trapani G, Biggio G.
    J Med Chem; 2002 Oct 10; 45(21):4655-68. PubMed ID: 12361392
    [Abstract] [Full Text] [Related]

  • 16. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
    Matzen L, van Amsterdam C, Rautenberg W, Greiner HE, Harting J, Seyfried CA, Böttcher H.
    J Med Chem; 2000 Mar 23; 43(6):1149-57. PubMed ID: 10737747
    [Abstract] [Full Text] [Related]

  • 17. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.
    du Jardin KG, Jensen JB, Sanchez C, Pehrson AL.
    Eur Neuropsychopharmacol; 2014 Jan 23; 24(1):160-71. PubMed ID: 23916504
    [Abstract] [Full Text] [Related]

  • 18. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.
    Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C.
    J Psychopharmacol; 2015 Oct 23; 29(10):1092-105. PubMed ID: 26174134
    [Abstract] [Full Text] [Related]

  • 19. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD.
    Psychopharmacology (Berl); 2007 Feb 23; 190(3):373-82. PubMed ID: 17242925
    [Abstract] [Full Text] [Related]

  • 20. Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT1A weak partial agonistic activity showing the antidepressant-like effect.
    Yoshinaga H, Masumoto S, Koyama K, Kinomura N, Matsumoto Y, Kato T, Baba S, Matsumoto K, Horisawa T, Oki H, Yabuuchi K, Kodo T.
    Bioorg Med Chem; 2017 Jan 01; 25(1):293-304. PubMed ID: 27865645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.